| Not Yet Recruiting | 5-Fluorouracil Response and Optimization STudy (The FROST Trial) NCT07419464 | Washington University School of Medicine | Phase 2 |
| Recruiting | Neoadjuvant CADI-05 in Combination With Pembrolizumab for Surgically Resectable Locally Advanced Head and Neck NCT07455032 | Fox Chase Cancer Center | Phase 1 |
| Not Yet Recruiting | Cetuximab Combined With Pembrolizumab or Finotonlimab and Chemotherapy in R/M HNSCC NCT07509099 | Ji Dongmei | Phase 3 |
| Not Yet Recruiting | Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab NCT04266730 | UNC Lineberger Comprehensive Cancer Center | Phase 1 |
| Not Yet Recruiting | Neoadjuvant Chemoimmunotherapy (Camrelizumab + Paclitaxel + Carboplatin) for Resectable HNSCC NCT07400094 | National Medical Research Radiological Centre of the Ministry of Health of Russia | Phase 2 |
| Recruiting | A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head NCT07219212 | Johnson & Johnson Enterprise Innovation Inc. | Phase 1 |
| Recruiting | A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants Wi NCT07276399 | Janssen Research & Development, LLC | Phase 3 |
| Recruiting | Phase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors NCT07151040 | One-carbon Therapeutics AB | Phase 1 / Phase 2 |
| Recruiting | A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Canc NCT07063212 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Withdrawn | Randomized Pre-surgical Window-of-Opportunity Trial of TTI-101 in Patients With Stage II-IV Resectable HPV-neg NCT05845307 | M.D. Anderson Cancer Center | EARLY_Phase 1 |
| Not Yet Recruiting | The Efficacy and Safety of Pucotenlimab Combined With TP Chemotherapy as Neoadjuvant Therapy for Locally Advan NCT06895369 | Sir Run Run Shaw Hospital | Phase 2 |
| Recruiting | HN-BIO 02: A Phase II Randomized Study of the Effects of Delayed Elective Radiotherapy on Head and Neck MRI an NCT06487403 | University Health Network, Toronto | N/A |
| Recruiting | Measurable Residual Disease Detection Using Tumor-Informed ctDNA Surveillance After Curative-Intent Treatment NCT06744296 | Massachusetts Eye and Ear Infirmary | — |
| Not Yet Recruiting | Neoadjuvant Toripalimab + Chemotherapy ± Cetuximab in Locally Advanced Head and Neck Squamous Cell Carcinoma ( NCT06647563 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | Phase 3 |
| Recruiting | A Study of DM005 in Patients With Advanced Solid Tumors NCT06515990 | Doma Biopharmaceutical（Suzhou）Co., Ltd. | Phase 1 |
| Recruiting | Reduction in the Number of Chemotherapy Cycles in Combination With Pembrolizumab in First-line Treatment of PD NCT06557889 | Institut Claudius Regaud | Phase 2 |
| Recruiting | Tumor-Informed ctDNA Testing for MRD Following Treatment of Squamous Cell Carcinoma NCT06606028 | University of California, San Francisco | — |
| Recruiting | 2 Courses of Concurrent Cisplatin Chemoradiotherapy After Surgery for High-risk Head and Neck Squamous Cell Ca NCT06492460 | Sun Yat-sen University | Phase 3 |
| Completed | A Study of SGN-B6A in Chinese Participants With Advanced Solid Tumors NCT06549816 | Seagen, a wholly owned subsidiary of Pfizer | Phase 1 |
| Recruiting | Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study NCT06534762 | Zhejiang Provincial People's Hospital | Phase 2 |
| Recruiting | A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer NCT06380816 | Cancer Research UK | Phase 1 / Phase 2 |
| Active Not Recruiting | A Phase 1b Study of WU-NK-101 in Combination With Cetuximab NCT05674526 | Wugen, Inc. | Phase 1 |
| Recruiting | A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cance NCT06385080 | Janssen Research & Development, LLC | Phase 1 / Phase 2 |
| Recruiting | European Larynx Organ Preservation Study (ELOS) [MK-3475-C44] NCT06137378 | University of Leipzig | Phase 2 |
| Active Not Recruiting | TBio-4101 and Pembro wi/ or w/o Chemo in Recurrent/Metastatic HNSCC NCT06236425 | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 |
| Recruiting | A Study of MGC026 in Participants With Advanced Solid Tumors NCT06242470 | MacroGenics | Phase 1 |
| Recruiting | App-based Recording and Optimization of the Nutritional Status in Patients With Head and Neck Tumors During an NCT06367257 | University of Erlangen-Nürnberg Medical School | N/A |
| Recruiting | Candida Therapeutic Vaccine in Head and Neck Cancer Patients to Reduce Recurrence NCT05952934 | University of Arkansas | Phase 2 |
| Withdrawn | Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recur NCT05743270 | Replimune, Inc. | Phase 2 |
| Recruiting | A Study of Head and Neck MRI and Tumor Microenvironment Biomarkers NCT06085781 | University Health Network, Toronto | N/A |
| Terminated | Study of Xevinapant With Radiation and Chemotherapy for Patients With Head and Neck Cancer NCT06110195 | University of Chicago | Phase 1 |
| Withdrawn | A Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122 Adenosine 2a Receptor NCT04892875 | Jennifer Choe | Phase 1 |
| Recruiting | Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable NCT05280314 | IO Biotech | Phase 2 |
| Terminated | Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck NCT06046482 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | Intraoperative Assessment of Surgical Margins Using Confocal Microscopy in Comparison With Reference Extempora NCT05935995 | Institut de Cancérologie de Lorraine | N/A |
| Terminated | Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Can NCT06034860 | Molecular Templates, Inc. | Phase 1 |
| Recruiting | Drug Screening Using Novel IMD in Salivary and Head and Neck Cancers NCT05553782 | Brigham and Women's Hospital | EARLY_Phase 1 |
| Not Yet Recruiting | PABLIXIMAB as Neoadjuvant Therapy for Head and Neck Squamous-cell Carcinoma NCT06125223 | Xijing Hospital | — |
| Recruiting | Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors W NCT06022757 | Evopoint Biosciences Inc. | Phase 1 / Phase 2 |
| Unknown | Toripalimab in Combined With Cetuximab，Chemotherapy for Conversion Therapy of Locally Nonresectable OCSCC NCT06081582 | First Affiliated Hospital of Zhejiang University | Phase 2 |
| Active Not Recruiting | Pilot Study of Imatinib Cetuximab Combo for H & N Cancer NCT05816785 | University of Wisconsin, Madison | EARLY_Phase 1 |
| Terminated | A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With Advanced Solid Tumor NCT05462873 | Novartis Pharmaceuticals | Phase 1 |
| Completed | A Standardized Intervention to Improve the Management of Chemotherapy-induced Nausea and Vomiting NCT05792228 | Tianjin Medical University Cancer Institute and Hospital | N/A |
| Recruiting | Single-Arm Exploratory Study of PD-L1 Antibody Plus Neoadjuvant Chemotherapy in Locally Advanced Head and Neck NCT07055841 | Xiuping Ding | Phase 2 |
| Recruiting | 5-Azacytidine and/or Nivolumab in Resectable HPV-Associated HNSCC NCT05317000 | Barbara Burtness | Phase 2 |
| Completed | Camrelizumab in Combination With Cetuximab and Chemotherapy for Relapsed/Metastatic HNSCC Patients NCT05673577 | Fudan University | Phase 2 |
| Recruiting | A Study to Evaluate the Safety and Tolerability of TOS-358 in Adults With HR+ Breast Cancer and Other Select S NCT05683418 | Totus Medicines | Phase 1 |
| Recruiting | A Study of SI-B001+SI-B003± Chemotherapy in Patients With Locally Advanced or Metastatic Head and Neck Squamou NCT05668858 | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 1 / Phase 2 |
| Terminated | A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours NCT05605522 | 3B Pharmaceuticals GmbH | Phase 1 |
| Active Not Recruiting | A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors NCT05653882 | Asher Biotherapeutics, Inc. | Phase 1 |
| Completed | A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the H NCT05271604 | BioAtla, Inc. | Phase 2 |
| Active Not Recruiting | A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advance NCT05544929 | Novartis Pharmaceuticals | Phase 1 |
| Active Not Recruiting | Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer NCT05620134 | Salubris Biotherapeutics Inc | Phase 1 / Phase 2 |
| Active Not Recruiting | Pembrolizumab Plus Olaparib in LA-HNSCC NCT05366166 | UNC Lineberger Comprehensive Cancer Center | Phase 2 |
| Active Not Recruiting | Prognostic Counselling in Palliative Head and Neck Cancer (ProCoPall) NCT06699316 | Erasmus Medical Center | N/A |
| Withdrawn | Quantifying Systemic Immunosuppression to Personalize Cancer Therapy NCT04941365 | Institut du Cancer de Montpellier - Val d'Aurelle | N/A |
| Active Not Recruiting | Reducing Excision Margins After Neoadjuvant Chemoimmunotherapy for HPV Negative Resectable Locally Advanced HN NCT05459415 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | N/A |
| Unknown | Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors NCT05311618 | NGM Biopharmaceuticals, Inc | Phase 1 |
| Completed | A Study of Setanaxib Co-Administered With Pembrolizumab in Patients With Recurrent or Metastatic Squamous Cell NCT05323656 | Calliditas Therapeutics Suisse SA | Phase 2 |
| Active Not Recruiting | Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced o NCT05215574 | NGM Biopharmaceuticals, Inc | Phase 1 |
| Recruiting | Quantifying Systemic Immunosuppression to Personalize Cancer Therapy NCT05621837 | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | — |
| Unknown | A Study of Docetaxel for Injection (Albumin-bound) in Combination With Nivolumab in Patients With Head and Nec NCT05027204 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Phase 1 / Phase 2 |
| Withdrawn | A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select NCT05234606 | Silverback Therapeutics | Phase 1 / Phase 2 |
| Completed | Decisional Conflicts, Health-related QoL and Satisfaction With Care in High-risk cSCC in the Head-neck Region NCT05482880 | Maastricht University Medical Center | — |
| Terminated | A Study of HC-7366 to Establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) NCT05121948 | HiberCell, Inc. | Phase 1 |
| Active Not Recruiting | ASP-1929 Photoimmunotherapy (PIT) Study in Patients With Recurrent Head/Neck Cancer NCT05182866 | Rakuten Medical, Inc. | Phase 2 |
| Completed | Safety, Tolerability and Pharmacokinetics Investigation of Stimotimagene Copolymerplasmid NCT05578820 | Gene Surgery LLC | Phase 1 |
| Recruiting | Study on the Efficacy of Treatment by Radiotherapy and Pembrolizumab in Newly Diagnosed Metastatic Head & Neck NCT04747054 | UNICANCER | Phase 3 |
| Terminated | Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Met NCT05099549 | NKGen Biotech, Inc. | Phase 1 / Phase 2 |
| Completed | Radiotherapy in Combination With Atezolizumab Prior to Surgical Resection for HPV Unrelated HNSCC NCT05053737 | University of Colorado, Denver | Phase 1 |
| Active Not Recruiting | Needs and Preferences of Patients With Head-neck Cutaneous SCC NCT06046625 | Maastricht University Medical Center | — |
| Terminated | A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With HNSCC (Ma NCT05061420 | Sanofi | Phase 2 |
| Completed | Window of Opportunity Study of Preoperative Immunotherapy With Atezolizumab in Local SCCHN NCT04939480 | University Hospital, Essen | Phase 2 |
| Completed | MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) NCT05007106 | Merck Sharp & Dohme LLC | Phase 2 |
| Completed | A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers NCT04879849 | Takeda | Phase 1 |
| Recruiting | A Beta-only IL-2 ImmunoTherapY Study NCT05086692 | Medicenna Therapeutics, Inc. | Phase 1 / Phase 2 |
| Recruiting | Dose De-escalation and Sentinel LN Mapping Driven Radiotherapy of Contralateral Neck in Ipsilateral Node Posit NCT04688528 | Universitaire Ziekenhuizen KU Leuven | N/A |
| Active Not Recruiting | Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Mal NCT04913337 | NGM Biopharmaceuticals, Inc | Phase 1 / Phase 2 |
| Completed | A Study to Assess Safety of Nivolumab in Routine Oncology Practice in China NCT04825873 | Bristol-Myers Squibb | — |
| Terminated | Study of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1 NCT04795713 | Molecular Templates, Inc. | Phase 1 |
| Recruiting | A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advan NCT04895709 | Bristol-Myers Squibb | Phase 1 / Phase 2 |
| Unknown | SHR-1701 in Patients With Recurrent/Metastatic Scchn NCT04650633 | Jiangsu HengRui Medicine Co., Ltd. | Phase 2 |
| Terminated | Optimisation of Potential Dental Implant Sites Protection for Rehabilitation in Patients With Head and Neck Ca NCT04801472 | Institut de cancérologie Strasbourg Europe | N/A |
| Withdrawn | Sleep Apnea in Head and Neck Cancer Patients at the University of Colorado NCT04922112 | University of Colorado, Denver | N/A |
| Unknown | Concurent Chemoradiotherapy in Head and Neck Cancers NCT04780750 | Assiut University | Phase 3 |
| Completed | A Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Participants NCT04665843 | Hoffmann-La Roche | Phase 2 |
| Unknown | Non Elective Vulnerable Elderly Radiotherapy NCT04832555 | Azienda Ospedaliero Universitaria Policlinico Modena | N/A |
| Terminated | Evaluation of Bintrafusp Alfa in Operable and Untreated Head and Neck Squamous Cell Carcinoma NCT04428047 | UNICANCER | Phase 2 |
| Completed | INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors NCT04580485 | Incyte Corporation | Phase 1 |
| Completed | Using MASL to Combat Oral Cancer NCT04188665 | Rowan University | EARLY_Phase 1 |
| Terminated | CMP-001 in Combination With Pembrolizumab in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell NCT04633278 | Regeneron Pharmaceuticals | Phase 2 |
| Withdrawn | A Multi-Cancer, Multi-State, Platform Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Pancreatic Ad NCT04262388 | University Health Network, Toronto | Phase 2 |
| Unknown | Albumin-bound Paclitaxel Combined With Cisplatin Versus Docetaxel Combined With Cisplatin Induced Chemotherapy NCT04766827 | Tianjin Medical University Cancer Institute and Hospital | Phase 4 |
| Recruiting | Optimised Early Management of Squamous Cell Carcinoma of the Head and Neck Cancer NCT04528420 | Centre Henri Becquerel | N/A |
| Terminated | TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy NCT04596033 | Genocea Biosciences, Inc. | Phase 1 |
| Completed | A Study of Pembrolizumab (MK-3475) Plus Carboplatin and Paclitaxel as First-line Treatment of Recurrent/Metast NCT04489888 | Merck Sharp & Dohme LLC | Phase 4 |
| Completed | GEN-001 (Live Biotherapeutic Product) and Avelumab Combination Study for Patients With Solid Tumors Who Have P NCT04601402 | Genome & Company | Phase 1 |
| Terminated | Study of REGN6569 and Cemiplimab in Adult Patients With Advanced Solid Tumor Malignancies NCT04465487 | Regeneron Pharmaceuticals | Phase 1 |
| Terminated | A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic NCT04260802 | Ocellaris Pharma, Inc. | Phase 1 / Phase 2 |
| Terminated | Ph1 Study of SL-172154 Administered Intratumorally in Subjects With Squamous Cell Carcinoma of the Head and Ne NCT04502888 | Shattuck Labs, Inc. | Phase 1 |
| Completed | A Study to Evaluate NT219 Alone and in Combination with ERBITUX® (Cetuximab) in Adults with Advanced Solid Tum NCT04474470 | TyrNovo Ltd. | Phase 1 / Phase 2 |
| Completed | Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatini NCT04428151 | Merck Sharp & Dohme LLC | Phase 2 |
| Active Not Recruiting | HYPORT: A Phase I/II Study of Hypofractionated Post-operative Radiation Therapy for Head and Neck Cancer NCT04403620 | University of Texas Southwestern Medical Center | Phase 1 / Phase 2 |
| Recruiting | A Study of Sigvotatug Vedotin in Advanced Solid Tumors NCT04389632 | Seagen, a wholly owned subsidiary of Pfizer | Phase 1 |
| Recruiting | Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven NCT04429542 | Bicara Therapeutics | Phase 1 |
| Terminated | Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractor NCT04348916 | Oncorus, Inc. | Phase 1 |
| Completed | Navigation vs Usual Care for Timely Adjuvant Therapy for Patients With Locally Advanced HNSCC NCT04030130 | Medical University of South Carolina | N/A |
| Completed | Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid NCT04344795 | Tempest Therapeutics | Phase 1 |
| Withdrawn | Monitoring Blood Flow and Metabolic Activity in Malignant Tissue of Head and Neck Region NCT04266470 | Wake Forest University Health Sciences | N/A |
| Completed | A Study of ALKS 4230 (Nemvaleukin Alfa) With Pembrolizumab in Head and Neck Cancer NCT04144517 | Mural Oncology, Inc | Phase 2 |
| Completed | sEphB4-HSA With RT+Chemo or Cetux in Patients With Intermediate to High Risk LAHNSCC NCT04091867 | University of Colorado, Denver | Phase 1 |
| Active Not Recruiting | A Clinical Trial Evaluating TG4050 in Head and Neck Cancer NCT04183166 | Transgene | Phase 1 / Phase 2 |
| Completed | A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors NCT03997968 | Cyteir Therapeutics, Inc. | Phase 1 / Phase 2 |
| Withdrawn | Enoblituzumab Plus MGA012 or MGD013 in Squamous Cell Carcinoma of the Head and Neck NCT04129320 | MacroGenics | Phase 2 / Phase 3 |
| Unknown | The Diagnostic Value of PET/MRI in Head and Neck Cancer NCT04117139 | Odense University Hospital | N/A |
| Completed | Navigation for Timely Adjuvant Therapy for Patients With Locally Advanced HNSCC NCT04098458 | Medical University of South Carolina | N/A |
| Completed | Analysis of Patterns of Recurrence in Head and Neck Cancer Using Clinicopathomic Markers NCT04086849 | Sunnybrook Health Sciences Centre | — |
| Completed | TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers NCT03829436 | Tempest Therapeutics | Phase 1 |
| Terminated | A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent NCT03829501 | Kymab Limited | Phase 1 / Phase 2 |
| Active Not Recruiting | NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy NCT03589339 | Nanobiotix | Phase 1 |
| Terminated | MGC018 With or Without MGA012 in Advanced Solid Tumors NCT03729596 | MacroGenics | Phase 1 / Phase 2 |
| Active Not Recruiting | A Trial Evaluating the Addition of Nivolumab to Cisplatin-RT for Treatment of Cancers of the Head and Neck NCT03576417 | Groupe Oncologie Radiotherapie Tete et Cou | Phase 3 |
| Terminated | A Phase 1/2 Study of FS118 in Patients With Advanced Malignancies NCT03440437 | invoX Pharma Limited | Phase 1 / Phase 2 |
| Completed | NIVolumab in Subjects With Recurrent or Metastatic Platinum-refrACTORy SCCHN NCT05802290 | Gruppo Oncologico del Nord-Ovest | Phase 3 |
| Completed | A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms NCT03219268 | MacroGenics | Phase 1 |
| Completed | Changes in Body Composition After EPA Supplementation in Head and Neck Patients NCT02715596 | Institut Català d'Oncologia | Phase 3 |
| Completed | Phase I Study of BYL719 in Combination With Cisplatin and Radiotherapy in Patients With Squamous Cell Head and NCT02537223 | University Health Network, Toronto | Phase 1 |
| Terminated | A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Ce NCT02479178 | BIND Therapeutics | Phase 2 |
| Completed | Study to Evaluate the Response Rate to Therapy With Docetaxel and Cisplatin in Unresectable Locally Advanced S NCT02061631 | Sanofi | Phase 2 |
| Active Not Recruiting | MicroRNA Markers in Head and Neck Cancers NCT04305366 | University of Colorado, Denver | — |
| Completed | A Phase I Study of LJM716 in Squamous Cell Carcinoma of Head and Neck, or HER2+ Breast Cancer or Gastric Cance NCT01598077 | Novartis Pharmaceuticals | Phase 1 |
| Completed | Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologi NCT01353625 | Celgene | Phase 1 |
| Unknown | Pemetrexed as Salvage Treatment in Squamous Cell Carcinoma of Head and Neck NCT01333696 | Fudan University | Phase 2 |
| Completed | Safety and Efficacy Study of P276-00 in Combination With Radiation in Subjects With Advanced Head and Neck Can NCT00899054 | Piramal Enterprises Limited | Phase 1 / Phase 2 |
| Completed | A Randomized Phase 2 Pharmacokinetic Trial of Chemotherapy With or Without Panitumumab in Patients With Metast NCT00756444 | Amgen | Phase 2 |
| Completed | A Phase II Clinical Trial to Study the Efficacy and Safety of a New Drug P276-00 in Treatment of Recurrent and NCT00824343 | Piramal Enterprises Limited | Phase 2 |
| Withdrawn | Dendritic Cell Vaccine for Head and Neck Cancer NCT00492947 | University of Maryland, Baltimore | Phase 1 |
| Completed | Docetaxel in Combination With Zactima (ZD6474) in Patients With Locally Advanced Squamous Cell Carcinoma of th NCT00459043 | Dana-Farber Cancer Institute | Phase 2 |
| Completed | A Study Of Lapatinib Versus Placebo Followed By Chemoradiation In Patients With Locally Advanced Head And Neck NCT00371566 | GlaxoSmithKline | Phase 2 |
| Completed | Study of Docetaxel in Combination With Cisplatin and 5-Fluorouracil in Locally Advanced Squamous Cell Carcinom NCT00139269 | Dana-Farber Cancer Institute | Phase 1 / Phase 2 |